Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Cheng, AL; Finn, RS; Qin, S; Han, KH; Ikeda, K; Piscaglia, F; Baron, AD; Park, JW; Han, GH; Jassem, J; Blanc, JF; Vogel, A; Komov, D; Evans, TRJ; -Lopez, CL; Dutcus, CE; Ren, M; Kraljevic, S; Tamai, T; Kudo, M

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索